Search research articles
Contact Us
Filters
Showing results (751-760 of 837) with videos related to
Page
of 84
Sort By:
Nature Biomedical Engineering
|
September 29, 2020
An electric-field-responsive paramagnetic contrast agent enhances the visualization of epileptic foci in mouse models of drug-resistant epilepsy
Cong Wang, Wanbing Sun, Jun Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 12, 2024
The dichotomous roles of microbial-modified bile acids 7-oxo-DCA and isoDCA in intestinal tumorigenesis
Xingchen Dong, Fei Sun, Henry Secaira-Morocho, et al.
Journal of Cardiovascular Electrophysiology
|
December 18, 2003
Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome
Wojciech Zareba, Arthur J Moss, Gloria Sheu, et al.
World Journal of Gastroenterology
|
June 11, 2025
Multi-parameter magnetic resonance imaging of zebularine in liver fibrosis treatment and calcineurin/<i>NFAT3</i> mechanism
Shi-Yi Lyu, Wang Xiao, Yan-Jing Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Timothy A Brighton, Amit Khot, Simon J Harrison, et al.
The Lancet. Oncology
|
December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
British Journal of Haematology
|
February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
Vania Hungria, Meral Beksac, Katja C Weisel, et al.
The Journal of Supportive Oncology
|
February 9, 2008
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia
Bertram Wiedenmann, Peter Malfertheiner, Helmut Friess, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 19, 2022
Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS
Weijun Fu, Wei Li, Jianda Hu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 10, 2021
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study
Jin Lu, Weijun Fu, Wei Li, et al.
Page
of 84
Search research articles
Search
Showing results (751-760 of 837) with videos related to
Sort By:
Page
of 84
Nature Biomedical Engineering
|
September 29, 2020
An electric-field-responsive paramagnetic contrast agent enhances the visualization of epileptic foci in mouse models of drug-resistant epilepsy
Cong Wang, Wanbing Sun, Jun Zhang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 12, 2024
The dichotomous roles of microbial-modified bile acids 7-oxo-DCA and isoDCA in intestinal tumorigenesis
Xingchen Dong, Fei Sun, Henry Secaira-Morocho, et al.
Journal of Cardiovascular Electrophysiology
|
December 18, 2003
Location of mutation in the KCNQ1 and phenotypic presentation of long QT syndrome
Wojciech Zareba, Arthur J Moss, Gloria Sheu, et al.
World Journal of Gastroenterology
|
June 11, 2025
Multi-parameter magnetic resonance imaging of zebularine in liver fibrosis treatment and calcineurin/<i>NFAT3</i> mechanism
Shi-Yi Lyu, Wang Xiao, Yan-Jing Chen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 21, 2019
Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Siltuximab in High-Risk Smoldering Multiple Myeloma
Timothy A Brighton, Amit Khot, Simon J Harrison, et al.
The Lancet. Oncology
|
December 6, 2021
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study
Saad Z Usmani, Hang Quach, Maria-Victoria Mateos, et al.
British Journal of Haematology
|
February 8, 2021
Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial
Vania Hungria, Meral Beksac, Katja C Weisel, et al.
The Journal of Supportive Oncology
|
February 9, 2008
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia
Bertram Wiedenmann, Peter Malfertheiner, Helmut Friess, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 19, 2022
Daratumumab, Bortezomib, and Dexamethasone versus Bortezomib and Dexamethasone in Chinese Patients With Relapsed or Refractory Multiple Myeloma: Updated Analysis of LEPUS
Weijun Fu, Wei Li, Jianda Hu, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 10, 2021
Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study
Jin Lu, Weijun Fu, Wei Li, et al.
Page
of 84